Selexis CHO Cells in Suspension-1

Archives

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

MAY 11, 2022
4 min read

Great Place to Work® Designates Selexis as a Best Workplace in Switzerland for Fifth Straight Year

Geneva, Switzerland, May 11, 2022Selexis SA, a JSR Life Sciences Company, announced today that Great Place to Work®...

Read More
MAY 2, 2022
7 min read

JSR Appoints Veteran Biotech and CDMO Leader Mark W. Womack to Lead KBI Biopharma and Selexis SA

SUNNYVALE, California, May 2, 2022 – JSR Life Sciences, LLC (JSR) today announced that Mark W. Womack will serve as...

Read More
MARCH 11, 2022
7 min read

Connect with Selexis at Upcoming Industry Events to Gain Pivotal Insights on Cell Line Development

Geneva, Switzerland, March 11, 2022Selexis SA, a JSR Life Sciences company, today announced that its business and...

Read More
FEBRUARY 9, 2022
4 min read

Launch of Generium’s Omalizumab Biosimilar for Atopic Bronchial Asthma Marks Selexis’ Ninth Commercial Product

Third Biosimilar to Reach the Market Under Selexis/Generium Commercial License Agreements

Geneva, Switzerland, and...

Read More
JANUARY 19, 2022
3 min read

Selexis and Inotrem Enter Service Agreement to Advance Inotrem’s Chronic Inflammatory Disease Program

Geneva, Switzerland, and Paris, France, January 19, 2022Selexis SA, a JSR Life Sciences company, and Inotrem SA, an...

Read More
JANUARY 12, 2022
4 min read

Hemogenyx Pharmaceuticals and Selexis SA Will Advance Hemogenyx’s Acute Myeloid Leukemia (AML) CDX Bispecific Antibody to Human Trials

Hemogenyx Pharmaceuticals will leverage Selexis’ SUREtechnology Platform™ of protein expression technologies and...

Read More
NOVEMBER 1, 2021
3 min read

Meet Selexis During Key Industry Conferences to Learn About the Latest Innovations in Cell Line Development

Geneva, Switzerland, November 1, 2021Selexis SA, a JSR Life Sciences company, today announced that business and...

Read More
JUNE 29, 2021
3 min read

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Geneva, Switzerland, and Durham, NC – June 29, 2021Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences...

Read More
JUNE 1, 2021
2 min read

Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business Officer

Business Development Executive in Biologics Drug Development and Manufacturing Brings More than 25 Years of...

Read More
MAY 27, 2021
3 min read

Great Place to Work® Designates Selexis as One of the Best Workplaces™ Switzerland for Fourth Straight Year

Geneva, Switzerland, May 27, 2021  Selexis SA, a JSR Life Sciences company, announced today that Great Place to Work® ...

Read More